Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. (Q50497309)

14 March 2018

title

Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. (English)

1 reference

14 March 2018

0 references

Yoshihisa Okada

1

1 reference

14 March 2018

Kanji Yamaguchi

2

1 reference

14 March 2018

Tomoki Nakajima

3

1 reference

14 March 2018

Taichiroh Nishikawa

4

1 reference

14 March 2018

Masayasu Jo

5

1 reference

14 March 2018

Yasuhide Mitsumoto

6

1 reference

14 March 2018

Hiroyuki Kimura

7

1 reference

14 March 2018

Takeshi Nishimura

8

1 reference

14 March 2018

Nozomi Tochiki

9

1 reference

14 March 2018

Kohichiroh Yasui

10

1 reference

14 March 2018

Hironori Mitsuyoshi

11

1 reference

14 March 2018

Masahito Minami

12

1 reference

14 March 2018

Keizo Kagawa

13

1 reference

14 March 2018

Takeshi Okanoue

14

1 reference

14 March 2018

Yoshito Itoh

15

1 reference

14 March 2018

publication date

1 February 2013

1 reference

14 March 2018

published in

Liver International

1 reference

14 March 2018

volume

33

1 reference

14 March 2018

issue

2

1 reference

14 March 2018

page(s)

301-311

1 reference

14 March 2018

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

cites work

1 reference

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

21 January 2018

1 reference

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

21 January 2018

1 reference

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

21 January 2018

1 reference

Rosuvastatin: a high-potency HMG-CoA reductase inhibitor

21 January 2018

1 reference

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

Update on statin-mediated anti-inflammatory activities in atherosclerosis

21 January 2018

1 reference

Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects

21 January 2018

1 reference

Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.

21 January 2018

1 reference

Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis

21 January 2018

1 reference

Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts.

21 January 2018

1 reference

Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins)

21 January 2018

1 reference

Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process.

21 January 2018

1 reference

Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats

21 January 2018

1 reference

Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.

21 January 2018

1 reference

RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis.

21 January 2018

1 reference

Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis.

21 January 2018

1 reference

Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells

21 January 2018

1 reference

Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.

21 January 2018

1 reference

Mild hepatic fibrosis in cholesterol and sodium cholate diet-fed rats

21 January 2018

1 reference

Comparative pharmacology of rosuvastatin

21 January 2018

1 reference

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat.

21 January 2018

1 reference

High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production

21 January 2018

1 reference

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.

21 January 2018

1 reference

Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands

21 January 2018

1 reference

Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

Beyond reasonable doubt: who is the culprit in lipotoxicity in NAFLD/NASH?

21 January 2018

1 reference

Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis

21 January 2018

1 reference

Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice

21 January 2018

1 reference

Statins activate AMP-activated protein kinase in vitro and in vivo

21 January 2018

1 reference

Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo

21 January 2018

1 reference

Effects of statins on endothelium and signaling mechanisms

21 January 2018

1 reference

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12033

1 reference

14 March 2018

PubMed ID

23295058

1 reference

14 March 2018